Kopaq

Iohexol, the active ingredient in Kopaq, is an iodinated contrast agent presented as an injectable solution for intraarterial, intrathecal, and intravenous use. It enhances radiographic contrast in patients undergoing angiography, computed tomography, myelography and other diagnostic imaging procedures. GNH USA supplies Kopaq as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Kopaq (iohexol) is an iodinated contrast agent used in radiographic imaging procedures. - Angiography: Improves vessel visualization by increasing X‑ray attenuation. - Computed tomography (CT) imaging: Enhances tissue contrast for better diagnostic detail. - Myelography: Provides clear delineation of spinal structures during contrast studies. - Other diagnostic imaging procedures requiring contrast: Facilitates visualization of anatomical structures.

Adverse reactions may occur following administration of iohexol.

Common Side Effects: - Warm sensation at injection site: transient feeling of heat or flushing. - Nausea: mild to moderate upset stomach. - Metallic taste: temporary alteration of taste perception.

Serious or Rare Side Effects: - Anaphylactic reaction: severe allergic response requiring immediate medical attention. - Contrast‑induced nephropathy: acute kidney injury in susceptible patients. - Cardiac arrhythmia: irregular heart rhythm potentially triggered by rapid injection.

Prior to using Kopaq, consider the following precautions. - Assess renal function: evaluate serum creatinine before administration. - Screen for iodine allergy: obtain a detailed allergy history. - Use lowest effective dose: limit volume to the amount necessary for imaging. - Monitor vital signs: observe for hypotension or arrhythmia during injection. - Avoid rapid injection in high‑risk patients: inject slowly as recommended. - Store at room temperature: keep in original container, protect from light and moisture.

Iohexol may interact with other medications or agents.

Major Interactions (Avoid): - Concurrent nephrotoxic drugs: may increase risk of renal injury. - High‑dose iodinated contrast within 24 h: cumulative iodine load. - Radioactive iodine therapy: interference with iodine uptake.

Moderate Interactions (Monitor Closely): - Diuretics: may affect renal clearance of contrast. - Beta‑blockers: may mask hypotensive response. - ACE inhibitors: potential additive effect on renal function.